Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12047564 | 0.92 | DPP4 (0.57) | DPP4CYP3A4CYP1A2CYP2D6KCNH2 | |
| SCHEMBL10067751 | 0.86 | DPP4 (0.64) | DPP4 | |
| SCHEMBL8206963 | 0.86 | DPP4 (0.62) | DPP4CYP3A4CYP1A2CYP2D6OPRM1 | |
| SCHEMBL8214898 | 0.86 | DPP4 (0.73) | DPP4CYP3A4CYP1A2CYP2D6OPRM1 | |
| SCHEMBL8212902 | 0.85 | DPP4 (0.65) | DPP4OPRM1OPRK1KCNH2 | |
| SCHEMBL8206433 | 0.84 | DPP4 (0.63) | DPP4CYP3A4CYP1A2CYP2D6OPRM1 | |
| SCHEMBL8212782 | 0.81 | DPP4 (0.52) | DPP4OPRM1OPRK1KCNH2 | |
| SCHEMBL8216730 | 0.81 | DPP4 (0.63) | DPP4CYP3A4KCNH2 | |
| SCHEMBL19154444 | 0.81 | DPP4 (0.61) | DPP4 | |
| SCHEMBL24509039 | 0.81 | DPP4 (0.61) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071583-B2 | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-06 | — | — | US | disclosed |
| US-20090325926-A1 | PYRROLO[3,2-D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| WO-2008017670-A1 | PYRROLO [3, 2 -D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325926-A1 | PYRROLO[3,2-D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 234/4885CYP1A2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.